Wall Street brokers expect CareDx, Inc (NASDAQ: CDNA – Get Rating) to post earnings per share of ($0.04) for the current fiscal quarter, Zacks reports. Three analysts provided earnings estimates for CareDx. CareDx reported earnings per share of $0.14 in the same quarter last year, suggesting a negative 128.6% year-over-year growth rate. The company is expected to release its next quarterly results on Monday, January 1.
Zacks Investment Research’s earnings per share calculations are an average average based on a survey of sell-side research firms that provide coverage for CareDx.
CareDx (NASDAQ: CDNA – Get Rating) last released its quarterly earnings data on Thursday, February 24. The company reported ($0.31) earnings per share (EPS) for the quarter, missing Thomson Reuters consensus estimate of ($0.19) by ($0.12). CareDx had a negative return on equity of 6.49% and a negative net margin of 10.35%. The company posted revenue of $79.22 million for the quarter, versus analyst estimates of $78.10 million. In the same quarter a year earlier, the company posted ($0.07) earnings per share. CareDx revenue for the quarter increased 35.1% year over year.
A number of brokerages have weighed in on CDNA. Zacks Investment Research upgraded CareDx shares from a “held” rating to a “strong sell” rating in a Thursday, January 13 research report. Raymond James lowered his price target on CareDx shares from $90.00 to $52.00 and set a “Strong Buy” rating for the company in a research report on Friday, February 25. BTIG Research lowered its price target on CareDx shares from $100.00 to $65.00 in a Monday, February 28 research report. Craig Hallum lowered his price target on CareDx shares from $106.00 to $87.00 in a Friday, February 25 research report. Finally, StockNews.com upgraded CareDx shares from a “hold” rating to a “sell” rating in a Friday, April 8 research report. Two investment analysts have assigned a sell rating to the stock, three have issued a buy rating and one has assigned a high buy rating to the company’s stock. According to MarketBeat.com, CareDx currently has an average rating of “Buy” and an average price target of $81.80.
In other CareDx news, Director Peter Maag sold 10,000 shares in a trade that took place on Monday, February 7. The shares were sold at an average price of $42.07, for a total value of $420,700.00. The sale was disclosed in a filing with the SEC, which is available via this link. Additionally, insider Reginald Seeto sold 814 shares in a trade that took place on Tuesday, February 1. The shares were sold at an average price of $42.13, for a total transaction of $34,293.82. The disclosure of this sale can be found here. In the past three months, insiders have sold 72,612 shares of the company valued at $2,826,811. Insiders hold 4.60% of the shares of the company.
Several large investors have recently changed their positions in the company. Putnam Investments LLC acquired a new equity position in CareDx in Q3 worth $1,448,000. CastleArk Alternatives LLC acquired a new equity position in CareDx in Q3 worth $4,545,000. Polar Asset Management Partners Inc. increased its holdings of CareDx shares by 89.9% in Q3. Polar Asset Management Partners Inc. now owns 166,145 shares of the company valued at $10,529,000 after purchasing an additional 78,645 shares last quarter. Cubist Systematic Strategies LLC increased its holdings of CareDx shares by 650.1% in Q3. Cubist Systematic Strategies LLC now owns 39,900 shares of the company valued at $2,528,000 after purchasing an additional 34,581 shares last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new equity position in CareDx in Q3 worth $385,000.
CareDx stock traded at $2.61 midday Friday, hitting $35.41. 738,326 shares were traded, against an average volume of 729,947. CareDx has a fifty-two week low of $27.87 and a fifty-two week high of $96.88. The stock has a market capitalization of $1.88 billion, a price-earnings ratio of -60.02 and a beta of 0.68. The stock’s 50-day simple moving average is $37.71 and its 200-day simple moving average is $44.90.
About CareDx (Get a rating)
CareDx, Inc discovers, develops and markets diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Get a Free Copy of the Zacks Research Report on CareDx (CDNA)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for CareDx Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for CareDx and related companies with MarketBeat.com’s free daily email newsletter.